Company Profile

Tolero Pharmaceuticals Inc
Profile last edited on: 10/19/17      CAGE: 6K5F9      UEI:

Business Identifier: Drug discovery based on genetic pathway abnormalities
Year Founded
2011
First Award
2012
Latest Award
2012
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2975 Executive Parkway Suite 320
Lehi, UT 84043
   (801) 285-6003
   bizdev@toleropharma.com
   www.toleropharma.com
Location: Single
Congr. District: 04
County: Utah

Public Profile

In December 2016 Sumitomo Dainippon Pharma Co. Ltd. anounced acquisition of privately held oncology firm Tolero Pharmaceuticals Inc. for cash up front, significant earn-outs based on development achievements and payment based on net sales. Tolero Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops novel therapeutics to treat and cure cancer and other life-threatening diseases in the United States. Its products include TP-0413 that targets a signaling pathway complicated in the regulation of serum iron levels for individuals suffering with chronic inflammatory diseases, such as cancer and rheumatoid arthritis; TP-0829, which targets a vital component of the B-cell receptor signaling pathway for the treatment of B-cell lymphomas, B-cell leukemia, and multiple myeloma; and TP-0903, a dual-targeted agent that inhibits two signaling pathways for pancreatic cancer cell growth and survival, and for the maintenance of the tumor stromal cells. The company’s products also comprise TP-0227 that targets a signaling pathway deregulated in cancer cells particularly in endometrial carcinomas; and TP-1149 that targets a cellular mechanism to render myeloma cells resistant to current therapeutic approaches. Tolero Pharmaceuticals, Inc. has strategic partnerships with MannKind Corporation and Eutropics, Inc.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 NIH $200,000
Project Title: Targeting Bmp Signaling With Tp-0413

Key People / Management

  Dallin M Anderson -- Founder, Chairman And President

  David J Bearss -- Founder and Chief Executive Officer

  Kevin J O'Neill -- Vice President, Product Development

  David O Taylor -- Vice President, Operations And Finance

  Daniel Von Hoff -- Senior Vice President, Clinical Development

  Steven L Warner -- Vice President, Drug Discovery and Development